Glaukos at Jefferies Conference: Eyeing Interventional Success

During the Jefferies Global Healthcare Conference 2025, Glaukos Corp (GKOS) outlined its strategy focusing on interventional glaucoma treatments, particularly the iDose, aiming to shift the treatment paradigm away from traditional eye drops. The company is prioritizing standalone iDose procedures to expand market reach beyond cataract combinations and is actively working to streamline Medicare reimbursement for the device, with some MACs already providing predictable payments. Glaukos aims to achieve free cash flow breakeven, expecting iDose to enhance gross margins as volumes increase, while continuing to invest in clinical trials and future product launches like the Trio system, with potential clearance by 2026; however, LCD changes have impacted the broader MIGS market, requiring a focus on standalone procedures to maximize ROI.

Analysis

Glaukos Corporation (GKOS) is strategically repositioning itself as a leader in interventional glaucoma treatment, aiming to fundamentally alter the existing paradigm reliant on traditional eye drops. This shift is spearheaded by the launch of its iDose sustained pharmaceutical implant, with a deliberate focus on standalone procedures to access a significantly larger market segment—approximately 12 million diagnosed and treated eyes—compared to combination cataract surgeries. The company reported encouraging progress in securing Medicare reimbursement for iDose, with three Medicare Administrative Contractors (MACs) representing roughly 40-45% of covered lives (Noridian, Novitas, First Coast) providing predictable payment and driving approximately 75% of Q1 iDose volumes. While other MACs are progressing, with professional fees observed across all regions typically ranging from $600 to $1,000, the company is actively working to streamline processes. Financially, Glaukos is targeting free cash flow breakeven in the short term, with iDose expected to be accretive to gross margins as sales volumes increase. First-quarter results demonstrated early operating leverage, with revenue growth of 25% outpacing operating expense growth of 12%. Key future catalysts include potential FDA approval to remove the single-use restriction on iDose later this year and the development of the Trio system for in-office iDose administration, anticipated for clearance by 2026. Despite challenges from LCD changes impacting the broader MIGS market, which removed an estimated 10-15% of procedures, Glaukos sees continued growth in standalone utilization of iStent Infinite and expects mid-single-digit growth in combination cataract MIGS after lapping these changes.

Key Decisions for Investors

• Investors should assess Glaukos based on its long-term strategy to drive adoption of interventional glaucoma treatments, particularly iDose, which targets a substantial market opportunity beyond traditional approaches.
• Monitor the progress of iDose reimbursement across the remaining Medicare Administrative Contractors and the execution of the commercial payer strategy, as these are critical for accelerating revenue growth and market penetration.
• Evaluate the company's trajectory towards achieving free cash flow breakeven and the anticipated gross margin accretion from iDose sales, alongside its ability to maintain operating leverage while investing in future growth initiatives.
• Key catalysts to watch include FDA decisions regarding the removal of the iDose single-use limitation and milestones related to the Trio in-office delivery system, both of which could significantly expand iDose's market potential.
• Consider the impact of ongoing LCD changes on the broader MIGS market, but also note Glaukos's focus on driving standalone procedure volume for both iDose and iStent Infinite as a mitigating growth factor.